3[1]Feher M, Elkeles R.Lipid modification and coronary heart disease in type 2 diabetes:different from the general population.Heart,1999,81:10-11.
4[2]Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III).JAMA,2001,285:2486-2497.
5[3]Holman R. The UKPDS: implications for the dyslipidaemic patient. Acta Diabetol,2001,38: S9-14.
6[4]Taskinen MR, Smith U. Lipid disorders in NIDDM: implications for treatment. Journal of Internal Medicine,1998,244:361-370.
7[5]Barnett AH.Dyslipidaemia in diabetes-A GP guide.Practitioner,2002,246:120-123.
9[7]Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med,1996,335:1001-1009.
10[8]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Survival Study (4S). Lancet,1994,344:1383-1389.
2Vaziri ND, Sato T, Liang K. Molecularme ehanism of altered cholesterol metabolism in rats with spontoneous focal glomenrulosclersos [ J ]. Kid Int, 2003, 63: 1756-1763.
3Metcalf PA, Baker JK, Scragg PK, et al. Microalbu minuria ina middle - aged workforce. Effect of hyperglycemia and athnicity [ J ]. Diabetes Care, 1993, 16: 1485.
4John S, Schiaich M, langenfeld M, et al. Incresed bioavailabilityof nitric oxide after lipid - lowering therapy in hypercholesterole micpatients : a randomized, placebo - controlled doubleblind study [ J ]. Circulation, 1998, 98: 211.
